XML 30 R61.htm IDEA: XBRL DOCUMENT v2.4.0.8
COLLABORATIVE ARRANGEMENTS (Details) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Research and Development Expense, Total $ 1,712 $ 1,158
RiconPharma LLC [Member]
   
Research and Development Expense, Total 700 200
Sofgen Pharmaceuticals [Member]
   
Research and Development Expense, Total $ 200